USD
+$0.00
(+0.00%
)At Close (As of Nov 26, 2025)
$336.54K
Market Cap
-
P/E Ratio
-0.03
EPS
$0.70
52 Week High
$0.00
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$8.2M |
| Total Revenue | $7.2M |
| Cost Of Revenue | $15M |
| Costof Goods And Services Sold | $15M |
| Operating Income | -$50M |
| Selling General And Administrative | $26M |
| Research And Development | $14M |
| Operating Expenses | $41M |
| Investment Income Net | - |
| Net Interest Income | -$5.7M |
| Interest Income | - |
| Interest Expense | $5.3M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $859K |
| Income Before Tax | -$50M |
| Income Tax Expense | $691K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$50M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$45M |
| Ebitda | -$44M |
| Net Income | -$50M |
| Field | Value (USD) |
|---|---|
| Total Assets | $35M |
| Total Current Assets | $25M |
| Cash And Cash Equivalents At Carrying Value | $16M |
| Cash And Short Term Investments | $16M |
| Inventory | $4.8M |
| Current Net Receivables | $1.4M |
| Total Non Current Assets | $9.6M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $3.3M |
| Other Non Current Assets | - |
| Total Liabilities | $63M |
| Total Current Liabilities | $56M |
| Current Accounts Payable | $1.5M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $43M |
| Total Non Current Liabilities | $6.7M |
| Capital Lease Obligations | $8.2M |
| Long Term Debt | - |
| Current Long Term Debt | $41M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $49M |
| Other Current Liabilities | $12M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$28M |
| Treasury Stock | - |
| Retained Earnings | -$584M |
| Common Stock | $4K |
| Common Stock Shares Outstanding | $2.6M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$48M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $859K |
| Capital Expenditures | $192K |
| Change In Receivables | - |
| Change In Inventory | -$744K |
| Profit Loss | - |
| Cashflow From Investment | -$192K |
| Cashflow From Financing | $53M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$50M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$8.2M |
| Total Revenue | $7.2M |
| Cost Of Revenue | $15M |
| Costof Goods And Services Sold | $15M |
| Operating Income | -$50M |
| Selling General And Administrative | $26M |
| Research And Development | $14M |
| Operating Expenses | $41M |
| Investment Income Net | - |
| Net Interest Income | -$5.7M |
| Interest Income | - |
| Interest Expense | $5.3M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $859K |
| Income Before Tax | -$50M |
| Income Tax Expense | $691K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$50M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$45M |
| Ebitda | -$44M |
| Net Income | -$50M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
T2 Biosystems, Inc. (TTOO) is an innovative in vitro diagnostics company headquartered in Lexington, Massachusetts, focused on transforming healthcare through its advanced pathogen detection technologies. The company offers a suite of diagnostic products that deliver rapid, accurate results, thereby enhancing clinical decision-making and improving patient outcomes. With a strategic presence in both domestic and international markets, T2 is well-positioned to tackle the rising demand for reliable diagnostic solutions amid an increasingly complex healthcare landscape. Committed to quality and continuous innovation, T2 Biosystems is set to be a significant player in the evolution of medical diagnostics.